Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 12/20 | 0.57 |
| ▸ | BCHE | P06276 | 9/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453301 | 0.86 | POLB (0.59) | POLBACHEBCHEALOX5MEN1 | |
| SCHEMBL2458150 | 0.85 | ACHE (0.74) | ACHEBCHEPRMT6 | |
| SCHEMBL8633227 | 0.77 | POLB (0.71) | POLBALOX5MEN1CHRM2CHRM4 | |
| SCHEMBL12655116 | 0.76 | ACHE (0.63) | ACHEBCHEPRMT6 | |
| SCHEMBL4999409 | 0.74 | ACHE (0.61) | ACHEBCHEPRMT6 | |
| SCHEMBL8007208 | 0.74 | ACHE (0.55) | ACHEBCHEPRMT6 | |
| SCHEMBL8011063 | 0.74 | ACHE (0.61) | ACHEBCHEPRMT6 | |
| SCHEMBL613164 | 0.74 | ACHE (0.55) | ACHEBCHEPRMT6 | |
| SCHEMBL6419073 | 0.74 | ACHE (0.55) | ACHEBCHEPRMT6 | |
| SCHEMBL8409986 | 0.74 | ACHE (0.61) | ACHEBCHEPRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142582-A | Synthetic method of methyl cyclopentenolone | 上海应用技术大学 | 2020-12-29 | — | — | CN | claimed |
| CN-106565642-A | Synthesis method of N,N-dimethyl-5-methylfurfurylamine | 广州百花香料股份有限公司 | 2017-04-19 | — | — | CN | claimed |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | claimed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-5212187-A | Antihistamines | ZYMA SA (CH) | 1993-05-18 | — | — | US | claimed |
| EP-0526395-A1 | Arylalkylamine derivatives, process for their preparation and pharmaceutical compositions containing them | Zyma SA (CH) | 1993-02-03 | — | — | EP | claimed |
| US-4710498-A | ANTIULCER AGENTS | IKEDA MOHANDO CO., LTD. (JP) | 1987-12-01 | — | — | US | claimed |
| CN-119614200-A | Titanium nitride/tungsten etching solution with long service life and high selectivity | 湖北兴福电子材料股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-1656983-B1 | Process for deacidification of a gas with an absorbing solution and fractional regeneration | IFP ENERGIES NOW (FR) | 2024-01-24 | — | — | EP | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11384078-B2 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| CN-112142582-A | Synthetic method of methyl cyclopentenolone | 上海应用技术大学 | 2020-12-29 | — | — | CN | disclosed |
| EP-0177016-B1 | PYRIDYLOXY DERIVATIVES | Ikeda Mohando Co., Ltd. (JP) | 1993-06-23 | — | — | EP | disclosed |
| US-5212187-A | Antihistamines | ZYMA SA (CH) | 1993-05-18 | — | — | US | disclosed |
| EP-0526395-A1 | Arylalkylamine derivatives, process for their preparation and pharmaceutical compositions containing them | Zyma SA (CH) | 1993-02-03 | — | — | EP | disclosed |
| EP-0478195-A1 | Dihydropyridazinones, pyridazinones and related compounds as fungicides | ROHM AND HAAS COMPANY (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0437480-A4 | METHOD AND APPARATUS FOR CONTINUOUS CHEMICAL REACTIONS | — | 1991-10-30 | — | — | EP | disclosed |
| EP-0437480-A1 | METHOD AND APPARATUS FOR CONTINUOUS CHEMICAL REACTIONS. | COMMW SCIENT IND RES ORG (AU) | 1991-07-24 | — | — | EP | disclosed |
| WO-1990003840-A1 | METHOD AND APPARATUS FOR CONTINUOUS CHEMICAL REACTIONS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1990-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384078-B2 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | IL5, CYP3A5, ABCB11 | POLB 4529/4885ACHE 353/4885BCHE 298/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | POLB 3263/4885ACHE 4676/4885BCHE 3624/4885 |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | CASP3, BAX, BAD | POLB 2345/4885ACHE 3732/4885BCHE 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.